Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Memantine. Merz.

Gavin J Kilpatrick1, Gary S Tilbrook

  • 1CeNeS Ltd, Compass House, Vision Park, Histon, Cambridge, UK. gavin.kilpatrick@cenes.co.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent.

Frontiers in pharmacology·2021
Same author

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures.

Frontiers in immunology·2021
Same author

A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.

Anesthesia and analgesia·2012
Same author

A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.

Anesthesia and analgesia·2011
Same author

CNS 7056: a novel ultra-short-acting Benzodiazepine.

Anesthesiology·2007
Same author

Drug development in anaesthesia: industrial perspective.

Current opinion in anaesthesiology·2006
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Memantine hydrochloride, an NMDA antagonist, is being developed for dementia, Alzheimer's disease, and neuropathic pain. Regulatory approvals and market launches for Alzheimer's disease and other indications are anticipated soon.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Memantine hydrochloride, an NMDA receptor antagonist, has a history of development for dementia.
  • Multiple pharmaceutical companies are investigating memantine for various neurological and ocular conditions.

Purpose of the Study:

  • To summarize the development status and anticipated regulatory milestones for memantine hydrochloride.
  • To highlight the diverse therapeutic applications under investigation for memantine.

Main Methods:

  • Review of clinical trial phases and regulatory submissions for memantine.
  • Analysis of market launch timelines and company-specific development plans.

Main Results:

  • European approval recommended for Alzheimer's disease treatment in February 2002.

Related Experiment Videos

  • Anticipated regulatory filings for neuropathic pain and ocular diseases in the coming years.
  • Projected market launch of Ebixa (memantine) in late 2002 for Alzheimer's disease.

    • Conclusions:

    • Memantine hydrochloride shows promise across multiple indications, including Alzheimer's disease and neuropathic pain.
    • Ongoing clinical trials and regulatory processes indicate a significant pipeline for memantine development.